Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

1.955 +0.055 (+2.89%)
Streaming Delayed Price Updated: 10:54 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Citius Pharmaceuticals, Inc. - Common Stock

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second... 
Via Newsfile
Analysts Hunt for Undervalued Biotech Stocks
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first... 
Via Newsfile
Topics Economy Initial Public Offering
Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval
Via AB Newswire
Bloodstream Infections - From Threats to Solutions
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second... 
Via Newsfile
Topics Death
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
Via Get News
Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024
Via AB Newswire
Biopharma Stocks Transformative Innovation for the Future of Health
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the first... 
Via Newsfile
Topics Artificial Intelligence
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Featured in Coverage of the EF Hutton Annual Global Conference
Via Investor Brand Network
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
Via Get News
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
Via AB Newswire
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
Via FinancialNewsMedia
Topics Death
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.